Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Start-up BiPar Seeks Fast Track In PARP Inhibition

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

You may also be interested in...



Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

All-cash deal could be worth up to $500 million in upfront and milestone payments.

Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

All-cash deal could be worth up to $500 million in upfront and milestone payments.

Workforce Needs Top California Trade Group’s Policy Agenda

Meanwhile, bio industry looks to Obama for short-term financial relief amid economic crisis.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

As Biopharma Seeks Broader IRA Orphan Exclusion, Study Urges Boosting Savings By Eliminating It

Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance

The History Behind The Drug-Device Combos Targeted By FTC

EU Critical Medicines List To Be Ready ‘Within Days’

See All
UsernamePublicRestriction

Register

PS067088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By